Non ST segment elevation acute coronary syndrome

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- Nexus Pharmaceuticals, Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg/100mL single-dose IV-bags. Tentative approval has been granted for concentrations of 12.5mg/250mL single-dose IV-bags. It is an AP-rated generic to AGGRASTAT®¥. “We look forward to expanding our product range in the cardiovascular and IV solution space,” said Usman Ahmed, President and CEO. “Being granted this approval is a milestone for us, but also for patients who want more transparency in the healthcare they receive. We eagerly anticipate bringing it to market in the coming months.” Nexus Pharmaceuticals’ Tirofiban Hydrochloride for Injection will be available in cartons of sole single-dose IV bags. About Tirofiban Hydrochloride for Injection Tirofiban Hydrochloride for Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome. For prescribing information, please see the following link. About Nexus Pharmaceuticals Inc. Nexus Pharmaceuticals Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art manufacturing facility in Wisconsin, visit . ¥AGGRASTAT® is a registered trademark of Medicure Inc.

PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that multiple abstracts, including data from a prospectively identified analysis of patients with diabetes in the MERLIN TIMI-36 study, have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2007, which will be held in Orlando, FL on November 4 - 7, 2007. Ranexa(R) (ranolazine extended-release tablets): Prospective Evaluation of the Prognostic Implications of Low Level Elevation of Cardiac Troponin Using a New Highly-sensitive Assay for Cardiac Troponin I: Results from the MERLIN TIMI-36 Trial; Oral abstract, Monday, November 5, 2007, 9:30 a.m. EST B-type Natriuretic Peptide and the Effect of Ranolazine in Patients with Non- ST Elevation Acute Coronary Syndromes in the MERLIN TIMI-36 Trial; Oral abstract, Monday, November 5, 2007, 10:00 a.m. EST Anti-Ischemic Effects of Ranolazine in Women: Results from the Randomized, Placebo-controlled MERLIN TIMI-36 Trial; Oral abstract, Tuesday, November 6, 2007, 10:00 a.m. EST Effect of Ranolazine on Hemoglobin A1c in the MERLIN TIMI-36 Randomized Controlled Trial; Oral abstract, Tuesday, November 6, 2007, 11:00 a.m. EST Baseline Clinical Risk and Recurrent Ischemia as Detected on Continuous ECG (CECG) Monitoring in Patients with non-ST-Elevation Acute Coronary Syndrome in the MERLIN TIMI-36 Trial; Poster, Wednesday, November 7, 2007, 9:30 - 11:00 a.m. EST Tecadenoson Ventricular Rate Control Using the Adenosine Receptor Agonist CVT 510 in the Goat Model of Atrial Fibrillation: Efficacy During Exercise and Synergistic Effects with Metoprolol; Oral abstract, Tuesday, November 6, 2007, 4:15 p.m. EST Additional information regarding the AHA Scientific Sessions 2007 can be accessed at About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use. Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements. CONTACT: John Bluth, Executive Director, Corporate Communications & Investor Relations of CV Therapeutics, Inc., +1-650-384-8850 Web site:

PALO ALTO, Calif., May 25 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that patient enrollment in the MERLIN TIMI-36 study of ranolazine is now complete, with over 6,500 patients enrolled. The company expects top line data from the study could be available in the first quarter of 2007. According to a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), if treatment with Ranexa(R) (ranolazine extended-release tablets) in this study is not associated with an adverse trend in death or arrhythmia compared to placebo, the study's safety database could support potential approval of Ranexa as first-line chronic angina therapy, even if the primary endpoint is not met. In addition, if the primary endpoint is met, Ranexa could potentially also be approved for treatment of acute coronary syndromes (ACS) and secondary prevention. "We are extremely pleased to have reached a significant landmark for this important clinical trial and appreciate the hard work of all of the MERLIN-TIMI 36 investigators and research coordinators worldwide," said Eugene Braunwald, M.D., distinguished Hersey Professor of Medicine, Harvard Medical School, Chairman, TIMI Study Group Brigham and Women's Hospital. Study Details MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in approximately 6,500 patients with non-ST elevation ACS treated with standard therapy. The primary efficacy endpoint in MERLIN TIMI-36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with Ranexa compared to placebo. Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients are enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also receive standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials. The completion of MERLIN TIMI-36 is based on achieving specific numbers of events. The trial is expected to continue until a pre-specified number of cases of cardiovascular death, myocardial infarction or severe recurrent ischemia have been observed, and a pre-determined number of deaths from any cause have occurred. Slower than anticipated event rates could delay our schedule for trial completion and results. About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor, for reduction of the risk of cardiovascular mortality or nonfatal myocardial infarction in patients with stable coronary artery disease and treatment of essential hypertension. CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been approved for marketing by any regulatory authorities. Except for the historical information contained herein, the matters set forth in this press release, including statements as to special protocol assessment agreements, conduct of clinical studies, study results, regulatory review and approval and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; special protocol assessment agreements; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements. CV Therapeutics, Inc. CONTACT: Christopher Chai, Vice President, Treasury and InvestorRelations, +1-650-384-8560, or media, John Bluth, Senior Director,Corporate Communications, +1-650-384-8850, both of CV Therapeutics, Inc. Web site: